ADA: Lilly's Trulicity tops Ozempic at keeping patients compliant, real-world data show

Eli Lilly is fighting hard to protect Trulicity's share against Novo Nordisk’s newest offerings in the GLP-1 class, and it’s breaking out real-world data to support its case.

A new real-world analysis, presented Saturday at the American Diabetes Association’s virtual annual meeting, showed that at the six-month mark, patients were doing a better job sticking to Trulicity than they were to once-weekly rivals Ozempic from Novo and Bydureon BCise from AstraZeneca.